REAL-WORLD DURABILITY OF AFLIBERCEPT 8 MG AND FARICIMAB IN INITIATORS VERSUS SWITCHERS: A Multicenter Retrospective Analysis.

چکیده

To evaluate real-world differences in treatment durability, functional, and anatomic outcomes in patients who initiated or switched to aflibercept 8 mg or faricimab. Patients were categorized into four cohorts: 1) initiators of aflibercept 8 mg, 2) initiators of faricimab, 3) switchers to…

متن کامل چکیده در سایت ناشر در دسترس است.

موضوعات مرتبط

• تصویربرداری و تشخیص
• رتینوپاتی دیابتی